Abstract

The most important criteria for developing novel drug delivery system are to achieve clinical efficacy.
Mucoadhesive polymer like chitosan can be employed to increase the residence time of formulation in the
nasal cavity. The study was undertaken to develop chitosan based mucoadhesive microsphere of
Ziprasidone Hydrochloride (fifth generation antipshychotic) as simple w/o emulsification-cross linking
process using liquid paraffin as external phase.Ten different formulations were developed. Results show
that as the concentration of polymer increases it affects the particle size, production yield, encapsulation
efficiency, swelling index, in-vitro mucoadhesion and in-vitro drug release of mucoadhesive
microspheres. The in vitro mucoadhesion of microspheres was investigated using freshly isolated goat
nasal mucosa. The mucoadhesion for M0, M1, M2, and M9 was tested. The Mucoadhesion property was
satisfactory. The M2 exhibited lowest mucoadhesion of 68.9%, and M0 displayed highest mucoadhesion
of 87.5%. The In Vitro release studies it revealed that 84.1% of drug release from formulation M1 at 7hrs.
The 50% of the drug was released from the formulation M2 and 70.67% from formulation M9.This
formulations were further used for SEM for particles size analysis, mucoadhesion test and in-vitro drug
release. The In-vitro % drug release data suggest that the maximum and sustained drug release was
obtained for formulation M1. Conclusively, the present study showed that Ziprasidone hydrochloride
chitosan microspheres can deliver intanasally which can improve the therapeutic outcome for the Epileptic
seizure.